Bionor Pharma completes Solon Eiendom acquisition
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Insight Weekly: Renewables lead capacity additions; bank mergers of equals up; nickel IPOs surge
Insight Weekly: Utilities face headwinds; S&P 500 dividend hikes likely; dollar poised for rally
Bionor Pharma ASA completed its acquisition of Oslo-based residential property developer Solon Eiendom AS.
The deal is part of a broader restructuring under which Bionor Pharma plans to change its name to Solon Eiendom and transfer its HIV research activities to a subsidiary.
